J Korean Assoc Oral Maxillofac Surg.  2023 Apr;49(2):59-60. 10.5125/jkaoms.2023.49.2.59.

Prolotherapy of the temporomandibular joint is denoted as a new health technology in Korea

• Lee W

• KMID: 2542210
• DOI: http://doi.org/10.5125/jkaoms.2023.49.2.59

Reference

References

1. Center for New Health Technology Assessment (NECA). 2023. Introduction of nHTA [Internet]. NECA;Seoul: Available from: https://nhta.neca.re.kr/nhta/eng/nhtaENG0101VA.ecg.

2. Hakala RV. 2005; Prolotherapy (proliferation therapy) in the treatment of TMD. Cranio. 23:283–8. https://doi.org/10.1179/crn.2005.040. DOI: 10.1179/crn.2005.040. PMID: 16353469.

3. Sit RW, Reeves KD, Zhong CC, Wong CHL, Wang B, Chung VC, et al. 2021; Efficacy of hypertonic dextrose injection (prolotherapy) in temporomandibular joint dysfunction: a systematic review and meta-analysis. Sci Rep. 11:14638. https://doi.org/10.1038/s41598-021-94119-2. DOI: 10.1038/s41598-021-94119-2. PMID: 34282199. PMCID: PMC8289855.

4. Memiş S. 2022; Evaluation of the effects of prolotherapy on condyles in temporomandibular joint hypermobility using fractal dimension analysis. J Korean Assoc Oral Maxillofac Surg. 48:33–40. https://doi.org/10.5125/jkaoms.2022.48.1.33. DOI: 10.5125/jkaoms.2022.48.1.33. PMID: 35221305. PMCID: PMC8890968.